BioCentury | Mar 4, 2013
Finance

EdRIP's exit mantra

As Edmond de Rothschild Investment Partners begins its second decade, it is moving to increase its footprint outside of Europe. With 18 life science exits since its inception in 2002, EdRIP believes its ability to...
BC Week In Review | Feb 25, 2013
Company News

AbCheck, Daiichi Sankyo deal

AbCheck will use its AbSieve phage and yeast display technologies to discover antibodies against an undisclosed number of cancer targets from Daiichi's U3 Pharma GmbH affiliate. U3 will have rights to any antibodies developed under...
BioCentury | Apr 11, 2011
Finance

A Remembrance: The venture capitalist as artist

A Remembrance: The venture capitalist as artist Jean Deleage was one of the privileged few who could count many firsts in his life. But he didn't just help start the biotech industry and then ride...
BioCentury | Mar 7, 2011
Strategy

Daiichi's U.S. comPlexx

Although Roche has worldwide rights to Plexxikon Inc. 's PLX4032 , the opportunity to jump start a U.S. commercial presence in cancer on the back of co-promotion rights is leading Daiichi Sankyo Co. Ltd. to acquire...
BioCentury | Oct 5, 2009
Finance

Ebb & Flow

Of the $6.9 billion in biotech debt raised thus far in 2009, $1.9 billion (28%) was raised in the last two weeks through four financings: three bumped up deals by Elan Corp. plc (NYSE:ELN), Incyte...
BC Innovations | Jun 25, 2009
Strategy

Science for export

Although every major university or institute would like to be located in a biotech hub and keep its discoveries close to home, only a few true hubs exist. For everyone else, the question is whether...
BC Week In Review | May 25, 2009
Company News

MorphoSys, Daiichi Sankyo deal

Daiichi Sankyo exercised its option to add two new undisclosed cancer targets to a 2006 deal to use MorphoSys' HuCAL technology to generate antibodies against targets from the pharma. Daiichi Sankyo acquired the new targets...
BC Week In Review | Mar 16, 2009
Company News

Igenica management update

Igenica Inc. , Burlingame, Calif.   Business: Antibodies, Cancer   Hired: Mike Rothe as CEO, formerly managing director and CSO of U3 Pharma AG  ...
BioCentury | Mar 16, 2009
Finance

Ebb & Flow

Companies from across the development spectrum closed private rounds last week, with the amounts raised largely illustrative of how far up or downstream each company finds itself. On one end was Victory Pharma , a specialty...
BioCentury | Nov 10, 2008
Finance

The denominator effect

Some of the largest public pension funds, crushed by losses in the public equity markets, are being forced to either reassess how they allocate their investments or rebalance their portfolios in order to maintain mandated...
Items per page:
1 - 10 of 37
BioCentury | Mar 4, 2013
Finance

EdRIP's exit mantra

As Edmond de Rothschild Investment Partners begins its second decade, it is moving to increase its footprint outside of Europe. With 18 life science exits since its inception in 2002, EdRIP believes its ability to...
BC Week In Review | Feb 25, 2013
Company News

AbCheck, Daiichi Sankyo deal

AbCheck will use its AbSieve phage and yeast display technologies to discover antibodies against an undisclosed number of cancer targets from Daiichi's U3 Pharma GmbH affiliate. U3 will have rights to any antibodies developed under...
BioCentury | Apr 11, 2011
Finance

A Remembrance: The venture capitalist as artist

A Remembrance: The venture capitalist as artist Jean Deleage was one of the privileged few who could count many firsts in his life. But he didn't just help start the biotech industry and then ride...
BioCentury | Mar 7, 2011
Strategy

Daiichi's U.S. comPlexx

Although Roche has worldwide rights to Plexxikon Inc. 's PLX4032 , the opportunity to jump start a U.S. commercial presence in cancer on the back of co-promotion rights is leading Daiichi Sankyo Co. Ltd. to acquire...
BioCentury | Oct 5, 2009
Finance

Ebb & Flow

Of the $6.9 billion in biotech debt raised thus far in 2009, $1.9 billion (28%) was raised in the last two weeks through four financings: three bumped up deals by Elan Corp. plc (NYSE:ELN), Incyte...
BC Innovations | Jun 25, 2009
Strategy

Science for export

Although every major university or institute would like to be located in a biotech hub and keep its discoveries close to home, only a few true hubs exist. For everyone else, the question is whether...
BC Week In Review | May 25, 2009
Company News

MorphoSys, Daiichi Sankyo deal

Daiichi Sankyo exercised its option to add two new undisclosed cancer targets to a 2006 deal to use MorphoSys' HuCAL technology to generate antibodies against targets from the pharma. Daiichi Sankyo acquired the new targets...
BC Week In Review | Mar 16, 2009
Company News

Igenica management update

Igenica Inc. , Burlingame, Calif.   Business: Antibodies, Cancer   Hired: Mike Rothe as CEO, formerly managing director and CSO of U3 Pharma AG  ...
BioCentury | Mar 16, 2009
Finance

Ebb & Flow

Companies from across the development spectrum closed private rounds last week, with the amounts raised largely illustrative of how far up or downstream each company finds itself. On one end was Victory Pharma , a specialty...
BioCentury | Nov 10, 2008
Finance

The denominator effect

Some of the largest public pension funds, crushed by losses in the public equity markets, are being forced to either reassess how they allocate their investments or rebalance their portfolios in order to maintain mandated...
Items per page:
1 - 10 of 37